Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature

详细信息    查看全文

• 作者：Catherine Atkin ; Philip Earwaker ; Arvind Pallan ; Shishir Shetty…
• 关键词：Sorafenib ; Hepatocellular carcinoma ; Hepatitis C virus infection
• 刊名：BMC Gastroenterology
• 出版年：2017
• 出版时间：December 2017
• 年：2017
• 卷：17
• 期：1
• 全文大小：1283KB
• 刊物主题：Gastroenterology; Internal Medicine; Hepatology;
• 出版者：BioMed Central
• ISSN：1471-230X
• 卷排序：17

文摘

BackgroundIn patients with advanced hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only systemic treatment that has been shown to increase overall survival. However, similar to other tyrosine kinase inhibitors, most patients achieve disease stabilisation radiologically, and only 2–3% of patients achieve a partial response. Recent exploratory subgroup analyses of the large phase 3 trials have demonstrated that patients with chronic hepatitis C virus (HCV) infection associated HCC survive longer than those who are negative for HCV. The mechanism underlying this currently remains unknown. A small number of cases of complete response to sorafenib treatment have now been reported worldwide, however a prolonged response has only been reported in 2 cases, both of whom had HCV-related HCC.